兴齐眼药：创新驱动，铸就业绩与ESG卓越典范

Core Viewpoint - Xingqi Eye Pharmaceutical achieved significant growth in both performance and ESG (Environmental, Social, and Governance) metrics in 2024, with a strong start in 2025, driven by product development and market expansion [1][2]. Financial Performance - In 2024, the company reported revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, marking the highest revenue since its listing; net profit reached 338 million yuan, up 40.84% year-on-year, also a record high [2]. - The eye drop segment generated 1.366 billion yuan in revenue in 2024, a remarkable growth of 106.08%, accounting for over 70% of total revenue, primarily due to the rapid sales of low-concentration atropine eye drops [2]. - In Q1 2025, the company achieved revenue of 536 million yuan, a year-on-year increase of 53.24%, and net profit of 146 million yuan, up 319.86% year-on-year, both setting new records since its listing [3]. Product Development and Market Strategy - The company focuses on various eye care products, including those for myopia control and dry eye treatment, with a 2024 R&D investment of 235 million yuan, a 29.55% increase from the previous year [2]. - The low-concentration atropine eye drops, approved in March 2024, are expected to have significant sales potential due to their effectiveness in slowing myopia progression among youth [3]. ESG Performance - Xingqi Eye Pharmaceutical has been recognized for its strong ESG performance, achieving A-level ratings in multiple assessments, reflecting its commitment to environmental protection, social responsibility, and corporate governance [5]. - In 2024, the company reduced its carbon emissions per unit of revenue by 17.77% and increased the proportion of clean energy usage from 6% to approximately 30% [5][6]. - The company invested 15.96 million yuan in public welfare in 2024, a 37.33% increase, and conducted 271 public welfare activities, serving over 208,800 individuals [8]. Future Outlook - For 2025, the company plans to continue increasing R&D investments, focusing on niche areas in ophthalmology and enhancing its product line, particularly in biologics for retinal diseases [4]. - The company aims to strengthen its production management and optimize processes across various dimensions to ensure high-quality development [4].